Ensysce Biosciences (ENSC) EPS (Basic) (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly EPS (Basic) of -$1.29 for Q3 2025, down 228.75% year-over-year from $1.0 in Q3 2024, and down 64.17% quarter-over-quarter from -$0.79 in Q2 2025.
Ensysce Biosciences (ENSC) EPS (Basic) (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported EPS (Basic) for 8 consecutive years, with -$1.29 the latest figure, recorded in Q3 2025.
- In Q3 2025, EPS (Basic) fell 228.75% year-over-year to -$1.29; the TTM figure through Dec 2025 stood at -$2.9 (up 74.7% YoY), while the FY2024 annual figure was -$11.45, up 83.74% from the prior year.
- EPS (Basic) retreated to -$1.29 in Q3 2025 per ENSC's latest filing, from -$0.79 in the prior quarter.
- Across five years, EPS (Basic) topped out at $1.0 in Q3 2024 and bottomed at -$2547.3 in Q3 2021.
- Historically, EPS (Basic) has averaged -$408.95 across 5 years, with a median of -$23.22 in 2023.
- Annual changes were most pronounced in 2021 — EPS (Basic) sank 1699.89% — and 2024, when it soared 107.68%.
- Ensysce Biosciences' EPS (Basic) stood at -$1935.4 in 2021, then surged by 76.22% to -$460.31 in 2022, then soared by 94.96% to -$23.22 in 2023, then soared by 77.99% to -$5.11 in 2024, then jumped by 74.71% to -$1.29 in 2025.
- Business Quant data shows ENSC's EPS (Basic) at -$1.29 in Q3 2025, -$0.79 in Q2 2025, and -$1.39 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.23 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.06 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.18 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -0.72 |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.29 |
| Jun 30, 2025 | -0.79 |
| Mar 31, 2025 | -1.39 |
| Dec 31, 2024 | -5.11 |
| Sep 30, 2024 | 1.00 |
| Jun 30, 2024 | -3.35 |
| Mar 31, 2024 | -8.21 |
| Dec 31, 2023 | -23.22 |
| Sep 30, 2023 | -13.07 |
| Jun 30, 2023 | -14.75 |
| Mar 31, 2023 | -31.25 |
| Dec 31, 2022 | -460.31 |
| Sep 30, 2022 | -923.72 |
| Jun 30, 2022 | -847.29 |
| Mar 31, 2022 | -219.88 |
| Dec 31, 2021 | -1,935.38 |
| Sep 30, 2021 | -2,547.27 |
| Jun 30, 2021 | -209.81 |
| Mar 31, 2021 | -525.00 |
| Dec 31, 2020 | 120.97 |